• 1
    Rusbridge C, McSweeney JE, Davies J, et al. Syringohydromyelia in Cavalier King Charles Spaniels. J Am Anim Hosp Assoc 2000;36:3441.
  • 2
    Capello R, Rusbridge C. Report from the Chiari-like malformation and syringohydromyelia working group. Vet Surg 2007;36:509512.
  • 3
    Rusbridge C, Jeffery ND. Pathophysiology and treatment of neuropathic pain associated with syringomyelia. Vet J 2008;175:164172.
  • 4
    Rusbridge C, Carruthers H, Dubé MP, et al. Syringomyelia in Cavalier King Charles spaniels: the relationship between syrinx dimensions and pain. J Small Anim Pract 2007;48:432436.
  • 5
    Hu HZ, Rusbridge C, Constantino-Casas F, Jeffrey N. Histopathological investigation of syringomyelia in the Cavalier King Charles Spaniel. J Comp Pathol 2011;146:192201.
  • 6
    Finnerup NB, Jensen TS. Spinal cord injury pain – mechanisms and treatment. Europ J Neurol 2004;11:7382.
  • 7
    DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001;90:16.
  • 8
    Pekny M. Glial cell function. In: Castellano-Lopez B, Nieto-Sampedro M, eds. Progress in Brain Research. Amsterdam: Elsevier; 2001;132:2330.
  • 9
    Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNFα. Science 2002;295:22822285.
  • 10
    Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev 2002;2:973985.
  • 11
    Ji RR, Strichart G. Cell signaling and the genesis of neuropathic pain. STKE 2004;252:reE14.
  • 12
    Yezierski RP. Spinal cord injury pain: spinal and supraspinal mechanism. J Rehab Res Dev 2009;46:95108.
  • 13
    Damm J, Wiegand F, Harden LM, et al. Fever, sickness behavior, and expression of inflammatory genes in the hypothalamus after systemic and localized subcutaneous stimulation of rats with the Toll-like receptor 7 agonist imiquimod. Neurosci 2012;201:166183.
  • 14
    Parker JE, Knowler SP, Rusbridge C, et al. Prevalence of asymptomatic syringomyelia in Cavalier King Charles Spaniels. Vet Rec 2011;168:667669.
  • 15
    Shults CW, Quirion R, Chronwall B, et al. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides 1984;5:10971128.
  • 16
    Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997;15:307339.
  • 17
    Parish CL, Finkelstein DI, Tripanichkul W, et al. The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. J Neurosci 2002;15:80348041.
  • 18
    Scholz J, Woolf CJ. The neuropathic pain triad: Neurons, immune cells, and glia. Nat Neurosci 2007;10:13611368.
  • 19
    Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-α. Nature 2006;440:10541059.
  • 20
    Ozaktay AC, Kallakuri R, Takebayashi T, et al. Effects of interleukin-1 beta, interleukin-6, and tumor necrosis factor on sensitivity of dorsal root ganglion and peripheral receptive fields in rats. Europ Spine J 2006;15:5866.
  • 21
    Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1b, interleukin-6, and tumor necrosis factor-α in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008;28:51895194.
  • 22
    Henry JL. Substance P and pain: An updating. Trends Neuroci 1980;3:9597.
  • 23
    Rusin KI, Ryu PD, Randic M. Modulation of excitatory amino acid responses in rat dorsal horn neurons by tachykinins. J Neurophysiol 1992;68:265286.
  • 24
    Hu HZ, Rusbridge C, Constantino-Casas F, Jeffery N. Distribution of substance P and calcitonin gene-related peptide in the spinal cord of Cavalier King Charles Spaniels affected by symptomatic syringomyelia. Res Vet Sci 2011;16:318320.
  • 25
    Yamada H, Yokota A, Haratake J, Horie A. Morphological study of experimental syringomyelia with kaolin-induced hydrocephalus in a canine model. J Neurosurg 1996;84:9991005.
  • 26
    Beric A. Central pain: “New” syndromes and their evaluation. Muscle Nerve 1993;16:10171024.
  • 27
    Christensen MD, Hulsebosch CE. Spinal cord injury and anti-NGF treatment results in changes in CGRP density and distribution in the dorsal horn in the rat. Exp Neurol 1997;147:463475.
  • 28
    Nurmikko TJ. Mechanisms of central pain. Clin J Pain 2000;5:96100.
  • 29
    Gwak YS, Nam TS, Paik KS, et al. Attenuation of mechanical hyperalgesia following spinal cord injury by administration of antibodies to nerve growth factor in the rat. Neurosci Lett 2003;336:117120.
  • 30
    Gadient RA, Otten UH. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997;52:379390.
  • 31
    Yeager MP, Lunt P, Arruda J, et al. Cerebrospinal fluid cytokine levels after surgery with spinal or general anesthesia. Reg Anest Pain Med 1992;24:557562.
  • 32
    Alexander GM, van Rijn MA, van Hilten JJ, et al. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005;116:213219.
  • 33
    Munts AG, Zijlstra FJ, Nibbering PH, et al. Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia. Clin J Pain 2008;24:3034.
  • 34
    Milhorat TH, Johnson RW, Milhorat RH. Clinicopathological correlations in syringomyelia using axial magnetic resonance imaging. Neurosurg 1995;37:206213.
  • 35
    Nakamura M, Chiba K, Nishizawa T, et al. Retrospective study of surgery-related outcomes in patients with syringomyelia associated with Chiari I malformation: clinical significance of changes in the size and localization of syrinx on pain relief. J Neurosurgery 2004;100:241e244.